Rises on Canada nod for staph infection treatment study

Aptorum

20/01/2021 11:48

** Pharmaceutical company's shares  APM.O  rise 8.4% to
$3.45 premarket
    ** Co receives clearance from Health Canada to begin
early-stage trial of its experimental drug, ALS-4, to treat
infections caused by Staphylococcus aureus or staph, a type of
bacteria that is resistant to several antibiotics (https://refini.tv/2Ma0IfH)
    ** Clearance granted to its subsidiary Aptorum International
Ltd
    ** Trial to be conducted in Canada and targeted to recruit
up to 48 and 24 healthy volunteers to test single and multiple
dose cohorts
    ** Stock up ~29% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))